Drugs & Aging

, Volume 27, Issue 3, pp 181–192

Mitochondrial Dynamics in Alzheimer’s Disease

Opportunities for Future Treatment Strategies
Leading Article

Abstract

The complexities that underlie the cognitive impairment and neurodegeneration characteristic of Alzheimer’s disease (AD) have yet to be completely understood, although many factors in disease pathogenesis have been identified. Particularly important in disease development seem to be mitochondrial disturbances. As pivotal role players in cellular metabolism, mitochondria are pertinent to cell survival and thus any deviation from their operation is certainly fatal. In this review, we describe how the dynamic balance of mitochondrial fission and fusion in particular is a necessary aspect of cell proliferation and that, as the cell ages, such balance is inevitably compromised to yield a destructive environment in which the cell cannot exist. Evidence for such disturbance is abundant in AD. Specifically, the dynamic balance of fission and fusion in AD is greatly shifted toward fission, and, as a result, affected neurons contain abnormal mitochondria that are unable to meet the metabolic demands of the cell. Moreover, mitochondrial distribution in AD cells is perinuclear, with few metabolic organelles in the distal processes, where they are normally distributed in healthy cells and are needed for exocytosis, ion channel pumps, synaptic function and other activities. AD neurons are thus characterized by increases in reactive oxidative species and decreases in metabolic capability, and, notably, these changes are evident very early in AD progression. We therefore believe that oxidative stress and altered mitochondrial dynamics contribute to the precipitation of AD pathology and thus cognitive decline. These implications provide a window for therapeutic intervention (i.e. mitochondrial protection) that has the potential to significantly deter AD progression if adequately developed. Current treatment strategies under investigation are described in this review.

References

  1. 1.
    Smith MA. Alzheimer disease. Int Rev Neurobiol 1998; 42: 1–54PubMedGoogle Scholar
  2. 2.
    Serretti A, Olgiati P, De Ronchi D. Genetics of Alzheimer’s disease: a rapidly evolving field. J Alzheimers Dis 2007 Aug; 12(1): 73–92PubMedGoogle Scholar
  3. 3.
    Rogaeva E, Kawarai T, George-Hyslop PS. Genetic complexity of Alzheimer’s disease: successes and challenges. J Alzheimers Dis 2006; 9(sn3 Suppl.): 381–7PubMedGoogle Scholar
  4. 4.
    Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, et al. Dissociated amyloid-β antibody levels as a serum bio-marker for the progression of Alzheimer’s disease: a population-based study. Exp Gerontol 2010; 45: 47–52PubMedGoogle Scholar
  5. 5.
    Iqbal K, Zaidi T, Thompson CH, et al. Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol (Berl) 1984; 62(3): 167–77Google Scholar
  6. 6.
    Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986 Jul; 83(13): 4913–7PubMedGoogle Scholar
  7. 7.
    Mancuso M, Orsucci D, Siciliano G, et al. Mitochondria, mitochondrial DNA and Alzheimer’s disease: what comes first? Curr Alzheimer Res 2008 Oct; 5(5): 457–68PubMedGoogle Scholar
  8. 8.
    Zhu X, Lee HG, Perry G, et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 2007 Apr;1772(4): 494–502PubMedGoogle Scholar
  9. 9.
    Wang X, Su B, Zheng L, et al. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Neurochem 2009 May; 109Suppl. 1: 153–9PubMedGoogle Scholar
  10. 10.
    Blass JP. The mitochondrial spiral: an adequate cause of dementia in the Alzheimer’s syndrome. Ann N Y Acad Sci 2000; 924: 170–83PubMedGoogle Scholar
  11. 11.
    Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 2006; 22: 79–99PubMedGoogle Scholar
  12. 12.
    Bleazard W, McCaffery JM, King EJ, et al. The dynaminrelated GTPase Dnm1 regulates mitochondrial fission in yeast. Nature Cell Biology 1999 Sep; 1(5): 298–304PubMedGoogle Scholar
  13. 13.
    Sesaki H, Jensen RE. Division versus fusion: Dnm1p and Fzo1p antagonistically regulate mitochondrial shape. J Cell Biol 1999 Nov 15; 147(4): 699–706PubMedGoogle Scholar
  14. 14.
    Twig G, Elorza A, Molina AJ, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008 Jan 23; 27(2): 433–46PubMedGoogle Scholar
  15. 15.
    Cheng X, Kanki T, Fukuoh A, et al. PDIP38 associates with proteins constituting the mitochondrial DNA nucleoid. J Biochem 2005 Dec; 138(6): 673–8PubMedGoogle Scholar
  16. 16.
    Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2007 Aug 10; 130(3): 548–62PubMedGoogle Scholar
  17. 17.
    Frank S, Gaume B, Bergmann-Leitner ES, et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 2001 Oct; 1(4): 515–25PubMedGoogle Scholar
  18. 18.
    Lee YJ, Jeong SY, Karbowski M, et al. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol Biol Cell 2004 Nov; 15(11): 5001–11PubMedGoogle Scholar
  19. 19.
    Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005 Jul 15; 280(28): 26185–92PubMedGoogle Scholar
  20. 20.
    McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol 2006 Jul 25; 16(14): R551–60PubMedGoogle Scholar
  21. 21.
    Parone PA, James DI, Da Cruz S, et al. Inhibiting the mitochondrial fission machinery does not prevent Bax/Bak-dependent apoptosis. Mol Cell Biol 2006 Oct; 26(20): 7397–408PubMedGoogle Scholar
  22. 22.
    Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 2006 Feb 21; 103(8): 2653–8PubMedGoogle Scholar
  23. 23.
    Chen H, Detmer SA, Ewald AJ, et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003 Jan 20; 160(2): 189–200PubMedGoogle Scholar
  24. 24.
    Benard G, Bellance N, James D, et al. Mitochondrial bioenergetics and structural network organization. J Cell Sci 2007 Mar 1; 120 (Pt 5): 838–48PubMedGoogle Scholar
  25. 25.
    Parone PA, Da Cruz S, Tondera D, et al. Preventing mitochondrial fission impairs mitochondrial function and leads to loss of mitochondrial DNA. PLoS ONE 2008; 3(9): e3257PubMedGoogle Scholar
  26. 26.
    Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006 Jun 30; 125(7): 1241–52PubMedGoogle Scholar
  27. 27.
    Knott AB, Perkins G, Schwarzenbacher R, et al. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 2008 Jul; 9(7): 505–18PubMedGoogle Scholar
  28. 28.
    Su B, Wang X, Zheng L, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 2010; 1802: 135–42PubMedGoogle Scholar
  29. 29.
    Smirnova E, Griparic L, Shurland DL, et al. Dynaminrelated protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 2001 Aug; 12(8): 2245–56PubMedGoogle Scholar
  30. 30.
    James DI, Parone PA, Mattenberger Y, et al. hFis1, a novel component of the mammalian mitochondrial fission machinery. J Biol Chem 2003 Sep 19; 278(38): 36373–9PubMedGoogle Scholar
  31. 31.
    Ishihara N, Eura Y, Mihara K. Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J Cell Sci 2004 Dec 15; 117 (Pt 26): 6535–46PubMedGoogle Scholar
  32. 32.
    Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004 May; 36(5): 449–51PubMedGoogle Scholar
  33. 33.
    Cipolat S, Martins de Brito O, Dal Zilio B, et al. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A 2004 Nov 9; 101(45): 15927–32PubMedGoogle Scholar
  34. 34.
    Chang CR, Blackstone C. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem 2007 Jul 27; 282(30): 21583–7PubMedGoogle Scholar
  35. 35.
    Cribbs JT, Strack S. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep 2007 Oct; 8(10): 939–44PubMedGoogle Scholar
  36. 36.
    Harder Z, Zunino R, McBride H. Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr Biol 2004 Feb 17; 14(4): 340–5PubMedGoogle Scholar
  37. 37.
    Karbowski M, Neutzner A, Youle RJ. The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J Cell Biol 2007 Jul 2; 178(1): 71–84PubMedGoogle Scholar
  38. 38.
    Meuer K, Suppanz IE, Lingor P, et al. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ 2007 Apr; 14(4): 651–61PubMedGoogle Scholar
  39. 39.
    Taguchi N, Ishihara N, Jofuku A, et al. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem 2007 Apr 13; 282(15): 11521–9PubMedGoogle Scholar
  40. 40.
    Cereghetti GM, Stangherlin A, Martins de Brito O, et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci U S A 2008 Oct 14; 105(41): 15803–8PubMedGoogle Scholar
  41. 41.
    Han XJ, Lu YF, Li SA, et al. CaM kinase I alpha-induced phosphorylation of Drp1 regulates mitochondrial morphology. J Cell Biol 2008 Aug 11; 182(3): 573–85PubMedGoogle Scholar
  42. 42.
    Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp 1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009 Apr 3; 324(923): 102–5PubMedGoogle Scholar
  43. 43.
    Frazier AE, Kiu C, Stojanovski D, et al. Mitochondrial morphology and distribution in mammalian cells. Biol Chem 2006 Dec; 387(12): 1551–8PubMedGoogle Scholar
  44. 44.
    Smirnova E, Shurland DL, Ryazantsev SN, et al. A human dynamin-related protein controls the distribution of mitochondria. J Cell Biol 1998 Oct 19; 143(2): 351–8PubMedGoogle Scholar
  45. 45.
    Griparic L, van der Wel NN, Orozco IJ, et al. Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria. J Biol Chem 2004 Apr 30; 279(18): 18792–8PubMedGoogle Scholar
  46. 46.
    Spinazzi M, Cazzola S, Bortolozzi M, et al. A novel deletion in the GTPase domain of OPA1 causes defects in mitochondrial morphology and distribution, but not in function. Hum Mol Genet 2008 Nov 1; 17(21): 3291–302PubMedGoogle Scholar
  47. 47.
    Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007 Feb; 292(2): C641–57PubMedGoogle Scholar
  48. 48.
    Zhu X, Lee HG, Casadesus G, et al. Oxidative imbalance in Alzheimer’s disease. Mol Neurobiol 2005; 31(1–3): 205–17PubMedGoogle Scholar
  49. 49.
    Ogawa O, Zhu X, Perry G, et al. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease. Sci Aging Knowledge Environ 2002 Oct 16; 2002(41): pe16PubMedGoogle Scholar
  50. 50.
    Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 1998; 105(8-9): 855–70PubMedGoogle Scholar
  51. 51.
    Chandrasekaran K, Giordano T, Brady DR, et al. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res Mol Brain Res 1994 Jul; 24(1-4): 336–40PubMedGoogle Scholar
  52. 52.
    Cottrell DA, Blakely EL, Johnson MA, et al. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 2001 Jul 24; 57(2): 260–4PubMedGoogle Scholar
  53. 53.
    Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 2000 May-Jun; 21(3): 455–62PubMedGoogle Scholar
  54. 54.
    Nagy Z, Esiri MM, LeGris M, et al. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol (Berl) 1999 Apr; 97(4): 346–54Google Scholar
  55. 55.
    Parker Jr WD, Mahr NJ, Filley CM, et al. Reduced platelet cytochrome c oxidase activity in Alzheimer’s disease. Neurology 1994 Jun; 44(6): 1086–90PubMedGoogle Scholar
  56. 56.
    Parker Jr WD, Parks J, Filley CM, et al. Electron transport chain defects in Alzheimer’s disease brain. Neurology 1994 Jun; 44(6): 1090–6PubMedGoogle Scholar
  57. 57.
    Coskun PE, Beal MF, Wallace DC. Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 2004 Jul 20; 101(29): 10726–31PubMedGoogle Scholar
  58. 58.
    Keller JN, Guo Q, Holtsberg FW, et al. Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J Neurosci 1998 Jun 15; 18(12): 4439–50PubMedGoogle Scholar
  59. 59.
    Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 2001 May 1; 21(9): 3017–23PubMedGoogle Scholar
  60. 60.
    Wang X, Su B, Fujioka H, et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol 2008 Aug; 173(2): 470–82PubMedGoogle Scholar
  61. 61.
    Wang X, Su B, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in susceptible neurons of Alzheimer disease [abstract]. Alzheimers Dement 2008; 4Suppl. 2: T645Google Scholar
  62. 62.
    Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 2002 Oct 25; 298(5594): 789–91PubMedGoogle Scholar
  63. 63.
    Sheehan JP, Swerdlow RH, Miller SW, et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer’s disease. J Neurosci 1997 Jun 15; 17(12): 4612–22PubMedGoogle Scholar
  64. 64.
    Stowers RS, Megeath LJ, Gorska-Andrzejak J, et al. Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein. Neuron 2002 Dec 19; 36(6): 1063–77PubMedGoogle Scholar
  65. 65.
    Melov S. Modeling mitochondrial function in aging neurons. Trends Neurosci 2004 Oct; 27(10): 601–6PubMedGoogle Scholar
  66. 66.
    Guo X, Macleod GT, Wellington A, et al. The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. Neuron 2005 Aug 4; 47(3): 379–93PubMedGoogle Scholar
  67. 67.
    Verstreken P, Ly CV, Venken KJ, et al. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 2005 Aug 4; 47(3): 365–78PubMedGoogle Scholar
  68. 68.
    Li Z, Okamoto K, Hayashi Y, et al. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004 Dec 17; 119(6): 873–87PubMedGoogle Scholar
  69. 69.
    Perry G, Smith MA. Is oxidative damage central to the pathogenesis of Alzheimer disease? Acta Neurol Belg 1998 Jun; 98(2): 175–9PubMedGoogle Scholar
  70. 70.
    Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000 Nov; 59(11): 1011–7PubMedGoogle Scholar
  71. 71.
    Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001 Aug; 60(8): 759–67PubMedGoogle Scholar
  72. 72.
    Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001 Jun 15; 21(12): 4183–7PubMedGoogle Scholar
  73. 73.
    Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997 Apr 24; 336(17): 1216–22PubMedGoogle Scholar
  74. 74.
    Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997 Mar; 48(3): 626–32PubMedGoogle Scholar
  75. 75.
    Odetti P, Angelini G, Dapino D, et al. Early glycoxidation damage in brains from Down’s syndrome. Biochem Biophys Res Commun 1998 Feb 24; 243(3): 849–51PubMedGoogle Scholar
  76. 76.
    Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998 May; 70(5): 2212–5PubMedGoogle Scholar
  77. 77.
    Kontush A, Berndt C, Weber W, et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001 Jan 1; 30(1): 119–28PubMedGoogle Scholar
  78. 78.
    Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998 May 22; 273(21): 12817–26PubMedGoogle Scholar
  79. 79.
    Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000 Jun 30; 275(26): 19439–42PubMedGoogle Scholar
  80. 80.
    Atwood CS, Smith MA, Martins RN, et al. Neuroin-flammatory environments promote amyloid-β deposition and posttranslational modification. In: Wood PL, editor. Neuroinflammation: mechanisms and management. 2nd ed. Totowa NJ): Humana Press Inc., 2003: 249–66Google Scholar
  81. 81.
    Petersen RB, Nunomura A, Lee HG, et al. Signal transduction cascades associated with oxidative stress in Alzheimer’s disease. J Alzheimers Dis 2007 May; 11(2): 143–52PubMedGoogle Scholar
  82. 82.
    Castegna A, Aksenov M, Thongboonkerd V, et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002 Sep; 82(6): 1524–32PubMedGoogle Scholar
  83. 83.
    Paola D, Domenicotti C, Nitti M, et al. Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 2000 Feb 16; 268(2): 642–6PubMedGoogle Scholar
  84. 84.
    Li HL, Wang HH, Liu SJ, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer’s neurodegeneration. Proc Natl Acad Sci U S A 2007 Feb 27; 104(9): 3591–6PubMedGoogle Scholar
  85. 85.
    Su B, Wang X, Nunomura A, et al. Oxidative stress signaling in Alzheimer’s disease. Curr Alzheimer Res 2008 Dec; 5(6): 525–32PubMedGoogle Scholar
  86. 86.
    Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985 Jun; 82(12): 4245–9PubMedGoogle Scholar
  87. 87.
    Wang X, Su B, Siedlak SL, et al. Amyloid-beta over-production causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 2008 Dec 9; 105(49): 19318–23PubMedGoogle Scholar
  88. 88.
    De Vos KJ, Allan VJ, Grierson AJ, et al. Mitochondrial function and actin regulate dynamin-related protein 1-dependent mitochondrial fission. Curr Biol 2005 Apr 12; 15(7): 678–83PubMedGoogle Scholar
  89. 89.
    Sandebring A, Thomas KJ, Beilina A, et al. Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS ONE 2009;4(5): e5701PubMedGoogle Scholar
  90. 90.
    Ichishita R, Tanaka K, Sugiura Y, et al. An RNAi screen for mitochondrial proteins required to maintain the morphology of the organelle in Caenorhabditis elegans. J Biochem 2008 Apr; 143(4): 449–54PubMedGoogle Scholar
  91. 91.
    Jendrach M, Mai S, Pohl S, et al. Short- and long-term alterations of mitochondrial morphology, dynamics and mtDNA after transient oxidative stress. Mitochondrion 2008 Sep; 8(4): 293–304PubMedGoogle Scholar
  92. 92.
    Frieden M, James D, Castelbou C, et al. Ca(2+) homeostasis during mitochondrial fragmentation and peri-nuclear clustering induced by hFis1. J Biol Chem 2004 May 21; 279(21): 22704–14PubMedGoogle Scholar
  93. 93.
    Szabadkai G, Simoni AM, Chami M, et al. Drp-1-dependent division of the mitochondrial network blocks intraorganellar Ca2+ waves and protects against Ca2+-mediated apoptosis. Mol Cell 2004 Oct 8; 16(1): 59–68PubMedGoogle Scholar
  94. 94.
    Lee S, Jeong SY, Lim WC, et al. Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence. J Biol Chem 2007 Aug 3; 282(31): 22977–83PubMedGoogle Scholar
  95. 95.
    Castellani RJ, Moreira PI, Liu G, et al. Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 2007 Oct; 32(10): 1640–5PubMedGoogle Scholar
  96. 96.
    Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009 Jul; 1790(7): 589–99PubMedGoogle Scholar
  97. 97.
    Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol 2006; 2006(3): 31372PubMedGoogle Scholar
  98. 98.
    Aliev G, Liu J, Shenk JC, et al. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 2009; 13: 320–33PubMedGoogle Scholar
  99. 99.
    Shenk JC, Liu J, Fischbach K, et al. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer’s disease. J Neurol Sci 2009 Aug 15; 283(1-2): 199–206PubMedGoogle Scholar
  100. 100.
    Long J, Gao F, Tong L, et al. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-L-carnitine. Neurochem Res 2009 Apr; 34(4): 755–63PubMedGoogle Scholar
  101. 101.
    Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 2002 Feb 19; 99(4): 2356–61PubMedGoogle Scholar
  102. 102.
    Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 2002 Feb 19; 99(4): 1876–81PubMedGoogle Scholar
  103. 103.
    Liu J, Atamna H, Kuratsune H, et al. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann N Y Acad Sci 2002 Apr; 959: 133–66PubMedGoogle Scholar
  104. 104.
    Liu J, Head E, Kuratsune H, et al. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress bio-markers in the brain of old rats. Ann N Y Acad Sci 2004 Nov; 1033: 117–31PubMedGoogle Scholar
  105. 105.
    Ames BN, Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann N Y Acad Sci 2004 Nov; 1033: 108–16PubMedGoogle Scholar
  106. 106.
    Milgram NW, Araujo JA, Hagen TM, et al. Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. FASEB J 2007 Nov; 21(13): 3756–62PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Department of PathologyCase Western Reserve UniversityClevelandUSA
  2. 2.UTSA Neurosciences Institute and Department of Biology, College of SciencesUniversity of Texas at San AntonioSan AntonioUSA

Personalised recommendations